Business Context and Reporting Period
This Form 6-K filing by The9 Limited (The9) covers the month of August 2026, with the report dated August 21, 2026. The filing serves to incorporate a press release by reference into Amendment No. 4 to the registration statement on Form F-3 (File No. 333-295089).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding a corporate event rather than a financial statement.
Material Changes
The primary material event disclosed is the advancement of The9's investee, Nanyang Biologics (NYB), toward a Nasdaq listing. This progress follows the clearing of a Request for Additional Information (RFAI) and a successful vote at NYB's Shareholders Extraordinary General Meeting.
Guidance, Outlook, and Risks
Management commentary is limited to the status of the investee's listing process. The filing does not contain specific financial guidance, outlook projections, or a discussion of risks and contingencies beyond the context of the investee's regulatory progress.
Investor Verification Checklist
- Verify the official Nasdaq listing status and timeline for Nanyang Biologics (NYB).
- Confirm the details of the Shareholders Extraordinary General Meeting vote regarding the listing.
- Review the specific content of the RFAI cleared by NYB to understand regulatory hurdles.
- Assess the potential financial impact of NYB's listing on The9's investment portfolio valuation.